These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37106163)

  • 81. Anti-CD19 CAR T Cells That Secrete a Biparatopic Anti-CLEC12A Bridging Protein Have Potent Activity Against Highly Aggressive Acute Myeloid Leukemia
    Rennert PD; Dufort FJ; Su L; Sanford T; Birt A; Wu L; Lobb RR; Ambrose C
    Mol Cancer Ther; 2021 Oct; 20(10):2071-2081. PubMed ID: 34253594
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia.
    Ataca Atilla P; McKenna MK; Tashiro H; Srinivasan M; Mo F; Watanabe N; Simons BW; McLean Stevens A; Redell MS; Heslop HE; Mamonkin M; Brenner MK; Atilla E
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32938629
    [TBL] [Abstract][Full Text] [Related]  

  • 83. A dual-receptor T-cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML.
    Dao T; Xiong G; Mun SS; Meyerberg J; Korontsvit T; Xiang J; Cui Z; Chang AY; Jarvis C; Cai W; Luo H; Pierson A; Daniyan A; Yoo S; Takao S; Kharas M; Kentsis A; Liu C; Scheinberg DA
    Blood; 2024 Feb; 143(6):507-521. PubMed ID: 38048594
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia.
    Gottschlich A; Thomas M; Grünmeier R; Lesch S; Rohrbacher L; Igl V; Briukhovetska D; Benmebarek MR; Vick B; Dede S; Müller K; Xu T; Dhoqina D; Märkl F; Robinson S; Sendelhofert A; Schulz H; Umut Ö; Kavaka V; Tsiverioti CA; Carlini E; Nandi S; Strzalkowski T; Lorenzini T; Stock S; Müller PJ; Dörr J; Seifert M; Cadilha BL; Brabenec R; Röder N; Rataj F; Nüesch M; Modemann F; Wellbrock J; Fiedler W; Kellner C; Beltrán E; Herold T; Paquet D; Jeremias I; von Baumgarten L; Endres S; Subklewe M; Marr C; Kobold S
    Nat Biotechnol; 2023 Nov; 41(11):1618-1632. PubMed ID: 36914885
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells.
    Myburgh R; Kiefer JD; Russkamp NF; Magnani CF; Nuñez N; Simonis A; Pfister S; Wilk CM; McHugh D; Friemel J; Müller AM; Becher B; Münz C; van den Broek M; Neri D; Manz MG
    Leukemia; 2020 Oct; 34(10):2688-2703. PubMed ID: 32358567
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Rapamycin Pretreatment Rescues the Bone Marrow AML Cell Elimination Capacity of CAR-T Cells.
    Nian Z; Zheng X; Dou Y; Du X; Zhou L; Fu B; Sun R; Tian Z; Wei H
    Clin Cancer Res; 2021 Nov; 27(21):6026-6038. PubMed ID: 34233960
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts.
    Cartellieri M; Feldmann A; Koristka S; Arndt C; Loff S; Ehninger A; von Bonin M; Bejestani EP; Ehninger G; Bachmann MP
    Blood Cancer J; 2016 Aug; 6(8):e458. PubMed ID: 27518241
    [TBL] [Abstract][Full Text] [Related]  

  • 88. BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia.
    Zhong M; Gao R; Zhao R; Huang Y; Chen C; Li K; Yu X; Nie D; Chen Z; Liu X; Liu Z; Chen S; Lu Y; Yu Z; Wang L; Li P; Zeng C; Li Y
    Cell Death Dis; 2022 Aug; 13(8):671. PubMed ID: 35918330
    [TBL] [Abstract][Full Text] [Related]  

  • 89. CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success.
    Fiorenza S; Turtle CJ
    BioDrugs; 2021 May; 35(3):281-302. PubMed ID: 33826079
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Novel Immune Cell-Based Therapies to Eradicate High-Risk Acute Myeloid Leukemia.
    Limongello R; Marra A; Mancusi A; Bonato S; Hoxha E; Ruggeri L; Hui S; Velardi A; Pierini A
    Front Immunol; 2021; 12():695051. PubMed ID: 34413848
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Targets for chimeric antigen receptor T-cell therapy of acute myeloid leukemia.
    Schorr C; Perna F
    Front Immunol; 2022; 13():1085978. PubMed ID: 36605213
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.
    Magnani CF; Turazzi N; Benedicenti F; Calabria A; Tenderini E; Tettamanti S; Giordano Attianese GM; Cooper LJ; Aiuti A; Montini E; Biondi A; Biagi E
    Oncotarget; 2016 Aug; 7(32):51581-51597. PubMed ID: 27323395
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Anti-CLL1-based CAR T-cells with 4-1-BB or CD28/CD27 stimulatory domains in treating childhood refractory/relapsed acute myeloid leukemia.
    Pei K; Xu H; Wang P; Gan W; Hu Z; Su X; Zhang H; He Y
    Cancer Med; 2023 Apr; 12(8):9655-9661. PubMed ID: 37031462
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Design and Production An Effective Bispecific Tandem Chimeric Antigen Receptor on T Cells against CD123 and Folate Receptor ß towards B-Acute Myeloid Leukaemia Blasts.
    Ghamari A; Pakzad P; Majd A; Ebrahimi M; Hamidieh AA
    Cell J; 2021 Nov; 23(6):650-657. PubMed ID: 34939758
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Preclinical Evaluation of CRISPR-Edited CAR-NK-92 Cells for Off-the-Shelf Treatment of AML and B-ALL.
    Ureña-Bailén G; Dobrowolski JM; Hou Y; Dirlam A; Roig-Merino A; Schleicher S; Atar D; Seitz C; Feucht J; Antony JS; Mohammadian Gol T; Handgretinger R; Mezger M
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361619
    [TBL] [Abstract][Full Text] [Related]  

  • 96. NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity.
    Richards RM; Zhao F; Freitas KA; Parker KR; Xu P; Fan A; Sotillo E; Daugaard M; Oo HZ; Liu J; Hong WJ; Sorensen PH; Chang HY; Satpathy AT; Majzner RG; Majeti R; Mackall CL
    Blood Cancer Discov; 2021 Nov; 2(6):648-665. PubMed ID: 34778803
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Chimeric antigen receptor T cell therapy in AML: How close are we?
    Gill S
    Best Pract Res Clin Haematol; 2016 Dec; 29(4):329-333. PubMed ID: 27890255
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Engineering tandem CD33xCD146 CAR CIK (cytokine-induced killer) cells to target the acute myeloid leukemia niche.
    Alberti G; Arsuffi C; Pievani A; Salerno D; Mantegazza F; Dazzi F; Biondi A; Tettamanti S; Serafini M
    Front Immunol; 2023; 14():1192333. PubMed ID: 37304257
    [TBL] [Abstract][Full Text] [Related]  

  • 99. CAR'TCR-T cells co-expressing CD33-CAR and dNPM1-TCR as superior dual-targeting approach for AML treatment.
    Teppert K; Yonezawa Ogusuku IE; Brandes C; Herbel V; Winter N; Werchau N; Khorkova S; Wöhle C; Jelveh N; Bisdorf K; Engels B; Schaser T; Anders K; Künkele A; Lock D
    Mol Ther Oncol; 2024 Jun; 32(2):200797. PubMed ID: 38601972
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Precision Immunotherapy Utilizing Adapter CAR-T Cells (AdCAR-T) in Metastatic Breast Cancer Leads to Target Specific Lysis.
    Önder CE; Moustafa-Oglou M; Schröder SM; Hartkopf AD; Koch A; Seitz CM
    Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.